{"id":414098,"date":"2025-11-17T00:00:00","date_gmt":"2025-11-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algowh0001-2025-biopharma-uterine-fibroids-current-treatment-treatment-algorithms-claims-data-analysis-uterine-fibroids\/"},"modified":"2026-03-31T10:24:16","modified_gmt":"2026-03-31T10:24:16","slug":"algowh0001-2025-biopharma-uterine-fibroids-current-treatment-treatment-algorithms-claims-data-analysis-uterine-fibroids","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algowh0001-2025-biopharma-uterine-fibroids-current-treatment-treatment-algorithms-claims-data-analysis-uterine-fibroids\/","title":{"rendered":"Uterine Fibroids &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Uterine Fibroids (US)"},"content":{"rendered":"<p>Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids\u2019 size. Progestins (e.g., norethindrone, levonorgestrel) in hormonal contraceptives and IUDs reduce heavy bleeding and cramping. Combination hormonal contraceptives (e.g., Sumitovant \/ Pfizer\u2019s Myfembree, approved in 2021) and antifibrinolytics, such as tranexamic acid, regulate menstrual cycles. Vitamins and supplements support health but do not impact fibroids. Gonadotropin-releasing hormone agonists modify hormone levels and shrink fibroids presurgery but have side effects limiting their long-term use. This analysis of patient-level claims data explores the use of various drug classes in both newly diagnosed and recently treated patients, providing insight into the current treatment of uterine fibroids in the United States.<\/p>\n<div>\n<p><strong>Questions answered<\/strong><\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW135590391 BCX8 round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed uterine fibroid patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed uterine fibroid patients?<\/li>\n<li>How have <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s, vitamins, progestins, combination hormonal contraceptives, antifibrinolytics, and other therapies been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of uterine fibroid patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of uterine fibroid patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<\/div>\n<div>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<div>\n<p><strong>Key drugs:<\/strong> <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s, vitamins, progestins, combination hormonal contraceptives, antifibrinolytics<\/p>\n<div>\n<p><strong>Product description<\/strong><\/p>\n<\/div>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW19165728 BCX8 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><span><strong>Product enhancement<\/strong><\/span><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n<div>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"template":"","class_list":["post-414098","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-uterine-fibroids","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/414098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/414098\/revisions"}],"predecessor-version":[{"id":561641,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/414098\/revisions\/561641"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=414098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}